Editorial office, European Journal of Clinical Oncology, India
Perspective
A systematic assessment of blood and neuroimaging indicators for cognitive side effects during chemotherapy in breast cancer patients
Author(s): Anamika Singh*
Blood- and neuroimaging-based indicators can change as a result of breast cancer treatment. For breast cancer survivors, a summary of the prognostic usefulness of these markers for cognition is missing. Following PRISMA guidelines, this systematic review summarised studies from the previous ten years that used the PubMed database to assess blood markers and the relationship between blood- or structural neuroimaging markers and cognition throughout the chemotherapy trajectory for primary breast cancer. There were 44 studies total. All blood marker categories showed variations from the start of chemotherapy to years after the end of the treatment. White and grey matter measurements in frontal, temporal, and parietal brain areas were linked to cognitive functioning, as were blood indicators (mostly inflammation-related) during, shortly after, or years postchemotherapy. There is prelimina.. View More»
DOI:
10.35248/clinical-oncology. 23.5(2).1-2
